GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives $8.78 Average Price Target from Brokerages

GoodRx Holdings, Inc. (NASDAQ:GDRX) has been given an average rating of “Hold” by the nineteen analysts that are covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $8.78.

A number of equities research analysts have commented on the company. Royal Bank of Canada raised their price objective on GoodRx from $7.00 to $8.00 and gave the company a “sector perform” rating in a research note on Friday, March 1st. SVB Leerink started coverage on GoodRx in a research report on Monday, February 26th. They set an “outperform” rating and a $8.00 target price on the stock. The Goldman Sachs Group lifted their target price on GoodRx from $6.50 to $7.50 and gave the company a “neutral” rating in a research report on Friday, March 1st. Truist Financial lifted their target price on GoodRx from $7.50 to $8.00 and gave the company a “hold” rating in a research report on Friday, March 1st. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of GoodRx in a research report on Monday, February 26th.

GoodRx Trading Up 3.5 %

Shares of GoodRx stock opened at $6.73 on Tuesday. The company has a debt-to-equity ratio of 0.85, a quick ratio of 7.12 and a current ratio of 7.12. GoodRx has a 52 week low of $4.14 and a 52 week high of $9.37. The stock has a 50 day moving average price of $6.89 and a two-hundred day moving average price of $6.20. The stock has a market capitalization of $2.66 billion, a PE ratio of -336.33, a price-to-earnings-growth ratio of 3.57 and a beta of 1.42.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings data on Thursday, February 29th. The company reported $0.02 EPS for the quarter, meeting analysts’ consensus estimates of $0.02. GoodRx had a positive return on equity of 2.45% and a negative net margin of 1.18%. The firm had revenue of $196.64 million during the quarter, compared to analysts’ expectations of $195.59 million. As a group, equities analysts anticipate that GoodRx will post 0.23 earnings per share for the current fiscal year.

Institutional Trading of GoodRx

Several hedge funds have recently made changes to their positions in GDRX. Tower Research Capital LLC TRC raised its stake in shares of GoodRx by 2,602.7% in the third quarter. Tower Research Capital LLC TRC now owns 6,919 shares of the company’s stock valued at $39,000 after buying an additional 6,663 shares during the period. Ensign Peak Advisors Inc bought a new stake in shares of GoodRx in the third quarter valued at $42,000. Citigroup Inc. raised its stake in shares of GoodRx by 301.7% in the third quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock valued at $45,000 after buying an additional 6,006 shares during the period. Creative Planning bought a new stake in shares of GoodRx in the fourth quarter valued at $50,000. Finally, Quadrature Capital Ltd bought a new stake in shares of GoodRx in the third quarter valued at $58,000. 63.77% of the stock is currently owned by institutional investors.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.